JP Morgan Chase
NBIX icon

JP Morgan Chase’s Neurocrine Biosciences NBIX Stock Holding History

JP Morgan Chase’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09B Buy
6,398,674
+956,607
+18% +$142M 0.06% 258
2026
Q1 		$701M Buy
5,442,067
+241,711
+5% +$32.1M 0.05% 334
2025
Q4 		$738M Buy
5,200,356
+470,204
+10% +$68.1M 0.05% 320
2025
Q3 		$664M Buy
4,730,152
+468,405
+11% +$63.5M 0.04% 361
2025
Q2 		$536M Buy
4,261,747
+1,590,749
+60% +$182M 0.04% 408
2025
Q1 		$295M Buy
2,670,998
+1,299,812
+95% +$165M 0.02% 547
2024
Q4 		$187M Sell
1,371,186
-126,745
-8% -$15.7M 0.01% 684
2024
Q3 		$173M Sell
1,497,931
-864,804
-37% -$119M 0.01% 739
2024
Q2 		$325M Buy
2,362,735
+67,627
+3% +$9.27M 0.03% 473
2024
Q1 		$317M Buy
2,295,108
+559,565
+32% +$76.4M 0.03% 507
2023
Q4 		$229M Sell
1,735,543
-75,694
-4% -$8.71M 0.02% 576
2023
Q3 		$204M Sell
1,811,237
-150,637
-8% -$15.9M 0.02% 547
2023
Q2 		$185M Sell
1,961,874
-194,135
-9% -$19M 0.02% 593
2023
Q1 		$218M Sell
2,156,009
-14,053
-0.6% -$1.46M 0.03% 515
2022
Q4 		$259M Sell
2,170,062
-201,175
-8% -$23.6M 0.03% 433
2022
Q3 		$252M Sell
2,371,237
-626,523
-21% -$63.6M 0.04% 419
2022
Q2 		$292M Sell
2,997,760
-7,549
-0.3% -$697K 0.04% 405
2022
Q1 		$282M Buy
3,005,309
+24,210
+0.8% +$2.05M 0.03% 459
2021
Q4 		$254M Buy
2,981,099
+291,601
+11% +$26.8M 0.03% 500
2021
Q3 		$258M Buy
2,689,498
+1,242,324
+86% +$117M 0.03% 500
2021
Q2 		$141M Sell
1,447,174
-88,637
-6% -$8.5M 0.02% 745
2021
Q1 		$149M Buy
1,535,811
+582,548
+61% +$61.1M 0.02% 676
2020
Q4 		$91.4M Buy
953,263
+187,785
+25% +$18.1M 0.01% 808
2020
Q3 		$74.8M Buy
765,478
+43,721
+6% +$5.06M 0.01% 802
2020
Q2 		$88.1M Buy
721,757
+259,846
+56% +$28.7M 0.02% 692
2020
Q1 		$40M Buy
461,911
+418,277
+959% +$40.9M 0.01% 902
2019
Q4 		$4.69M Buy
43,634
+12,023
+38% +$1.26M ﹤0.01% 2728
2019
Q3 		$2.85M Buy
31,611
+19,953
+171% +$1.86M ﹤0.01% 3170
2019
Q2 		$961K Sell
11,658
-601,218
-98% -$49.4M ﹤0.01% 3896
2019
Q1 		$54M Buy
612,876
+349,164
+132% +$29.2M 0.01% 914
2018
Q4 		$18.8M Buy
263,712
+47,737
+22% +$4.57M ﹤0.01% 1533
2018
Q3 		$26.6M Sell
215,975
-255,355
-54% -$29M 0.01% 1439
2018
Q2 		$46.3M Buy
471,330
+8,720
+2% +$781K 0.01% 1007
2018
Q1 		$38.4M Sell
462,610
-79,969
-15% -$6.75M 0.01% 1081
2017
Q4 		$42.1M Buy
542,579
+12,331
+2% +$841K 0.01% 1073
2017
Q3 		$31.5M Sell
530,248
-49,773
-9% -$2.63M 0.01% 1204
2017
Q2 		$26.7M Sell
580,021
-229,690
-28% -$11.1M 0.01% 1262
2017
Q1 		$35.1M Sell
809,711
-153,034
-16% -$6.56M 0.01% 1125
2016
Q4 		$37.3M Sell
962,745
-49,683
-5% -$2.25M 0.01% 1072
2016
Q3 		$51.3M Sell
1,012,428
-234,476
-19% -$11.7M 0.01% 818
2016
Q2 		$56.7M Buy
1,246,904
+590,549
+90% +$27.2M 0.01% 795
2016
Q1 		$26M Buy
656,355
+102,630
+19% +$4.07M 0.01% 1170
2015
Q4 		$31.3M Buy
553,725
+284,827
+106% +$14.5M 0.01% 1049
2015
Q3 		$10.7M Sell
268,898
-8,898
-3% -$430K ﹤0.01% 1711
2015
Q2 		$13.3M Buy
277,796
+79,823
+40% +$3.38M ﹤0.01% 1711
2015
Q1 		$7.86M Buy
197,973
+84,708
+75% +$3.03M ﹤0.01% 2054
2014
Q4 		$2.53M Buy
+113,265
New +$2.15M ﹤0.01% 2833
2014
Q2 		– Sell
-140,449
Closed -$2.26M – 3589
2014
Q1 		$2.26M Buy
140,449
+12,450
+10% +$213K ﹤0.01% 2495
2013
Q4 		$1.2M Sell
127,999
-39,117
-23% -$382K ﹤0.01% 3058
2013
Q3 		$1.89M Sell
167,116
-8,961
-5% -$123K ﹤0.01% 2843
2013
Q2 		$2.36M Buy
+176,077
New +$2.16M ﹤0.01% 2695

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

JP Morgan Chase's NBIX Position: Q2 2026 in Review

JP Morgan Chase increased its Neurocrine Biosciences (NBIX) stake by 18% in Q2 2026, buying an estimated $142M and bringing the position to 6,398,674 shares worth $1.09B. The position accounts for 0.06% of the portfolio, ranked #258.

JP Morgan Chase first reported a position in NBIX in Q2 2013 and has held it in 51 quarters since. 774 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • JP Morgan Chase held 6,398,674 shares of Neurocrine Biosciences worth $1.09B as of Q2 2026.
  • JP Morgan Chase bought 956,607 Neurocrine Biosciences shares in Q2 2026, an estimated $142M.
  • Neurocrine Biosciences made up 0.06% of JP Morgan Chase's portfolio in Q2 2026, its #258 holding.
  • JP Morgan Chase first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 51 quarters since.
  • 774 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.